HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon Q2

This article was originally published in The Rose Sheet

Executive Summary

Net sales advanced 0.9% to $321.1 mil. for the second quarter (ended June 30), and adjusted EBITDA was a loss of $20 mil. versus prior-year period adjusted EBITDA of $24 mil., firm states in Aug. 3 release. Results are in line with preliminary estimates announced July 10, when the company projected that returns of the Vital Radiance skin care brand would hamper sales, resulting in flat revenues for the quarter and an EBITDA loss of $30 mil. (1"The Rose Sheet" July 17, 2006, p. 3). Revlon experienced an operating loss in the quarter of $45.9 mil. and a net loss of $87.1 mil., firm adds. U.S. sales were down 0.6% to $180 mil. in the quarter, and international revenues increased 3% to $141 mil. due to growth in Latin America, the firm notes...

You may also be interested in...



Vital Radiance Efforts Intended To Boost Brand Following Difficult Q2

Revlon is renewing plans for Vital Radiance, focusing resources behind the brand's revised retail format, its most productive products and most effective marketing drivers, the company reported during a preliminary second quarter earnings call July 10

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014126

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel